ADMA Biologics: Strong Product Mix, Growing Margins And Compelling Upside

Company Overview - ADMA Biologics is a vertically integrated U.S. Immune Globulin plasma manufacturer [1] - The company's earnings are growing due to higher finished-goods yield from each liter of plasma and a mix shift [1] Investment Strategy - The investment approach focuses on quantitative and fundamental analysis, particularly in small to mid-cap stocks [1] - A value-investing strategy is adopted, emphasizing the importance of not overpaying for stocks to mitigate risk [1] - Stocks are typically held until growth prospects diminish or the price-to-earnings ratio justifies a sale [1]